• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Angion Biomedica Corp. (Amendment)

    2/10/23 4:53:03 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGN alert in real time by email
    SC 13G/A 1 d413932dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2

    (Amendment No. 1)*

     

     

    Angion Biomedica Corp

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    03476J107

    (CUSIP Number)

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐    Rule 13d-1(b)

    ☒    Rule 13d-1(c)

    ☐    Rule 13d-1(d)

     

    * 

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03476J107    13G    Page 1 of 5

     

      1.    

      NAMES OF REPORTING PERSONS

     

      Thomas A. Satterfield, Jr.

      2.  

      CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

      (a)  ☐        (b)  ☐

      3.  

      SEC USE ONLY

     

      4.  

      CITIZENSHIP OR PLACE OF ORGANIZATION

     

      United States of America

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5.    

      SOLE VOTING POWER

     

      308,647

       6.  

      SHARED VOTING POWER

     

      1,904,796

       7.  

      SOLE DISPOSITIVE POWER

     

      308,647

       8.  

      SHARED DISPOSITIVE POWER

     

      1,904,796

      9.    

      AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

      2,213,383

    10.  

      CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

      ☐

    11.  

      PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

      7.35%*

    12.  

      TYPE OF REPORTING PERSON

     

      IN

     

    *

    Based on 30,113,703 shares of common stock of the issuer outstanding as of November 8, 2022, as reported by the issuer in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, and assumes the exercise of the 15,558 Warrants beneficially owned by Satterfield Vintage Investments, LP.


    CUSIP No. 03476J107    13G    Page 2 of 5

     

    SCHEDULE 13G

    Item 1.

     

      (a)

    Name of Issuer:

    Angion Biomedica Corp

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    51 Charles Lindbergh Boulevard

    Uniondale, New York 11553

    Item 2.

     

      (a)

    Name of Person Filing:

    Thomas A. Satterfield, Jr.

     

      (b)

    Address of Principal Business Office or, if none, Residence:

    Thomas A. Satterfield, Jr.

    15 Colley Cove Drive

    Gulf Breeze, Florida 32561

     

      (c)

    Citizenship:

    Incorporated by reference from Item 4 of the Cover Page.

     

      (d)

    Title of Class of Securities:

    Incorporated by reference from the Cover Page.

     

      (e)

    CUSIP Number:

    Incorporated by reference from the Cover Page.

     

    Item 3.

    If this statement is filed pursuant to §§ 240.13d-1(b) or §§ 240.13d-2(b) or (c), check whether the person filing is a:

    Not Applicable.

     

    Item 4.

    Ownership.

     

      (a)

    Amount beneficially owned:

    Incorporated by reference from Item 9 of the Cover Page.

     

      (b)

    Percent of class:

    Incorporated by reference from Item 11 of the Cover Page.


    CUSIP No. 03476J107    13G    Page 3 of 5

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote

    Incorporated by reference from Item 5 of the Cover Page.

     

      (ii)

    Shared power to vote or to direct the vote

    Incorporated by reference from Item 6 of the Cover Page.

     

      (iii)

    Sole power to dispose or to direct the disposition of

    Incorporated by reference from Item 7 of the Cover Page.

     

      (iv)

    Shared power to dispose or to direct the disposition of

    Incorporated by reference from Item 8 of the Cover Page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following  ☐.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person.

    With respect to the beneficial ownership reported for Thomas A. Satterfield, Jr., 300,000 shares are held by Tomsat Investment & Trading Co., Inc., a corporation controlled by Mr. Satterfield and of which he serves as President; 732,178 shares are held by Caldwell Mill Opportunity Fund, which fund is managed by an entity of which Mr. Satterfield owns a 50% interest and serves as Chief Investment Manager; and 600,000 shares are held by A.G. Family L.P., a partnership managed by a general partner controlled by Mr. Satterfield.

    Additionally, Mr. Satterfield has limited powers of attorney for voting and disposition purposes with respect to the following securities: Satterfield Vintage Investments LP (200,000 shares and 15,558 warrants); Rebecca A. Satterfield (25,000 shares); and George and Laura Thaggard Pontikes (32,000 shares). These individuals and entities have the right to receive or the power to direct the receipt of the proceeds from the sale of their respective shares.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

     

    Item 8.

    Identification and Classification of Members of the Group.

    Not Applicable.


    CUSIP No. 03476J107    13G    Page 4 of 5

     

    Item 9.

    Notice of Dissolution of Group.

    Not Applicable.

     

    Item 10.

    Certifications.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    CUSIP No. 03476J107    13G    Page 5 of 5

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    February 10, 2023

    Date
    /s/ Thomas A. Satterfield, Jr.

    Thomas A. Satterfield, Jr.

    Get the next $ANGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGN

    DatePrice TargetRatingAnalyst
    12/10/2021$15.00 → $8.00Outperform
    Oppenheimer
    11/9/2021$100.00 → $50.00Buy
    HC Wainwright & Co.
    10/27/2021$40.00 → $15.00Buy
    Stifel
    More analyst ratings

    $ANGN
    SEC Filings

    View All

    Angion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    2/2/24 8:51:10 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/17/24 8:35:57 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/16/24 7:59:58 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Demuth Peter

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:39 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haqq Christopher

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Piekos Brian

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:51 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ANGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ANGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

    NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion's common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new trading symbol "ELTX." As a result of the reverse stock split, the CUSIP number for Angion's common stock will now be 28657F103. The reverse stock split was previously approved by the stockholders of Ang

    6/1/23 8:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

    UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listin

    12/21/22 9:50:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer reiterated coverage on Angion Biomedica with a new price target

    Oppenheimer reiterated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $8.00 from $15.00 previously

    12/10/21 7:18:08 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Angion Biomedica with a new price target

    HC Wainwright & Co. reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $50.00 from $100.00 previously

    11/9/21 7:47:50 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel reiterated coverage on Angion Biomedica with a new price target

    Stifel reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $15.00 from $40.00 previously

    10/27/21 8:24:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chudnovsky Yekaterina bought $7,047,530 worth of shares (1,213,000 units at $5.81) (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    12/26/23 4:29:30 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Financials

    Live finance-specific insights

    View All

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

    -- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GU

    12/9/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

    UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these

    10/26/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/27/23 4:07:01 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/26/23 4:25:31 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    8/30/23 5:16:05 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care